Across TCGA pan-cancer cohorts, MAP3K3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAP3K3 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAP3K3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP3K3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where MAP3K3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.790	0.489	.008	21	view →
CCRCC	DFS	Tertile	All	1.000	0.558	.003	13	view →
GBM	DFS	Quartile	All	0.652	0.240	.002	9	view →
PDAC	DFS	Median	II,III,IV	0.196	0.470	.006	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MAP3K3 tumor-vs-normal RNA expression · all MAP3K3 data types